First published 10/3/2026, 12:56:15 AM · Last updated 10/3/2026, 12:56:15 AM

P1.11.11 Survival Impact of Pneumonitis in Older Patients With Non-Squamous NSCLC Treated With Pembrolizumab and Pemetrexed: Insights From CJLSG1901

A peer-reviewed journal article reports analysis of how pneumonitis affects survival among older adults with non-squamous non‑small cell lung cancer receiving combined pembrolizumab and pemetrexed, using data from the CJLSG1901 study. The provided source metadata identifies the publisher but includes no further study details in the excerpt supplied to Planet Briefing.

Categories: public-health, science-and-space

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 4/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 1/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 3/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 3/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 3/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 2/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

Results speak to treatment outcomes for older patients with non-squamous NSCLC receiving pembrolizumab plus pemetrexed.

Sources

P1.11.11 Survival Impact of Pneumonitis in Older Patients With Non-Squamous NSCLC Treated With Pembrolizumab and Pemetrexed: Insights From CJLSG1901

Report an issue